Lilly opens all six Zepbound vial doses to cash-paying patients at $349 to $499 a month

On July 7, 2025, Eli Lilly opened all six approved strengths of Zepbound (tirzepatide) single-dose vials to cash-paying patients through LillyDirect, its direct-to-consumer platform. The 2.5 mg starting dose costs $349 a month, and the other five strengths cost $499 a month or less, with no insurance required ^[3][2].

Lilly announced the expansion on June 16, 2025, saying health care providers could begin prescribing the 12.5 mg and 15 mg vials on July 7, with shipments to patients starting in early August ^[3]. Until then, the self-pay vial program — called Zepbound Self Pay Pharmacy Solutions, or the Zepbound Self Pay Journey Program — covered only the lower strengths. With the two highest doses added, every approved strength (2.5, 5, 7.5, 10, 12.5 and 15 mg) is available for $499 a month or less to any eligible adult with a valid prescription, "regardless of insurance," the company said ^[3].

The $499 price is conditional. Lilly said the 7.5, 10, 12.5 and 15 mg vials are reduced to $499 for the first fill and for refills purchased within 45 days of the prior delivery. Without on-time refills, the monthly prices Lilly listed are $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg and $1,049 for 15 mg ^[3]. Walmart, which became the program's first retail pickup point, described the same structure in October 2025: $349 for 2.5 mg, $499 for the other doses, and the 45-day Self Pay Journey conditions for doses above 5 mg ^[2].

Prices at launch did not last. A timeline of the program says Lilly cut self-pay pricing effective December 1, 2025, to $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 through 15 mg, keeping the 45-day refill condition for the higher doses; missing that window now reverts those fills to $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg ^[1]. Those figures reflect a later point in time than the July 2025 launch prices, not a dispute about what launched.

Lilly said its direct-to-consumer pricing is "50 percent or greater" below the list price of other GLP-1 obesity medicines ^[2]. About 35% of new Zepbound prescriptions in the second quarter of 2025 were filled through LillyDirect, according to Walmart's announcement ^[2].

Why it matters for patients

The change turned LillyDirect from a starter-dose offer into a full-range cash alternative to insurance. People with no drug coverage, people whose commercial plan excludes weight-loss drugs, and Medicare and Medicaid enrollees — who are barred from manufacturer copay cards but can pay cash — can use it ^[1]. Eligibility does not involve an income test or an insurance-status questionnaire; patients must be 18 or older, live in the US or Puerto Rico, have a prescription for an FDA-approved use, and agree not to bill insurance or seek reimbursement for those fills ^[1].

The practical risk is the refill clock. One month is defined as 28 days, and the 45-day window runs from the delivery date of the previous shipment, not the order date, leaving roughly a 17-day buffer ^[1]. Stretching doses past a week, waiting on a new prescription after a dose change, or switching pharmacies mid-cycle can push a refill past the deadline and raise the price ^[1]. Single-dose vials are sold only through this self-pay channel, not through insurance-billed retail pharmacy, and syringes are sold separately ^[1].

What happens next

Shipments of the 12.5 mg and 15 mg vials began in early August 2025 ^[3]. Walmart pharmacies nationwide were scheduled to offer in-store pickup at the same self-pay prices by mid-November 2025, across nearly 4,600 locations ^[2]. Lilly has said it can amend or end the program at any time ^[1]. Whether prices change again, and by how much, has not been disclosed.